Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo

Phase 1Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Drug-Related Side Effects and Adverse Reactions

Conditions

Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease

Trial Timeline

Apr 24, 2017 → Feb 29, 2020

NCT ID

NCT03098680

About Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo

Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo is a phase 1 stage product being developed by AstraZeneca for Drug-Related Side Effects and Adverse Reactions. The current trial status is terminated. This product is registered under clinical trial identifier NCT03098680. Target conditions include Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03098680	Phase 1	Terminated	Apr 24, 2017	Feb 29, 2020	Drug-Related Side Effects and Adverse Reactions